Drugs / VALNIVUDINE
VALNIVUDINE
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02322957 | Feb → Apr 2015 | herpes zoster | ContraVir Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00900783 | May 2009 → Nov 2010 | herpes zoster | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02412917 | Jun 2015 → Nov 2017 | herpes zoster, postherpetic neuralgia | ContraVir Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VALNIVUDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300944 ↗ |
| Known as | FV-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00900783 ↗ |
| Known as | FV-100 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300944 ↗ |
| Known as | Valnivudina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300944 ↗ |
| Known as | VALNIVUDINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300944 ↗ |
| Modality | Small molecule | — CHEMBL4300944 ↗ |